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We previously reported that the ApoE e4e4 genotype was associated with COVID-19 test 
positivity (OR=2.31, 95% CI: 1.65 to 3.24, p=1.1910-6) [1] in the UK Biobank (UKB) cohort, during the 
epidemic peak in England, from March 16 to April 26, 2020 [2]. With more COVID-19 test results 
(March 16 to May 31, 2020) and mortality data (to March 31, 2020, with incomplete data for April, 2020) 
linked to UKB, we re-evaluated the ApoE e4 allele association with COVID-19 test positivity, and with 
all-cause mortality following test-confirmed COVID-19. 
We restricted analyses to European-ancestry participants [3] (n=451,367, 90% of sample) 
attending baseline assessment centers in England (n=398,073) and excluded participants who died before 
the pandemic (set at February 1, 2020, n=22,384). Single nucleotide polymorphism data for rs429358 and 
rs7412 were used to determine ApoE genotypes. Our outcomes of interest were: a) COVID-19 test 
positive versus the rest of the sample meeting inclusion criteria (i.e., including untested samples and 
tested negative), and b) tested positive and died versus the rest of the sample as above, but with additional 
exclusion of test positive participants who survived. Some of the excluded samples could have died but 
cannot be identified due to incomplete mortality data for April, 2020. Logistic regression models 
compared ApoE e4e4 participants (or e3e4s) to e3e3s with adjustment for sex; age on April 26th or age at 
death; baseline UKB assessment center in England (accounting for geographical differences in viral 
exposures); genotyping array type; and the top five genetic principal components (accounting for possible 
population admixture).  
The mean attained age was 68.2 years (SD=8.0) with 174,667 females (55%). Of 219,747 e3e3 
participants, 663 participants tested positive (302 per 100,000), of whom, 79 later died. Similarly, of 
8,767 e4e4 participants, 59 tested positive (673 per 100,000), of whom 13 later died (Table 1). In logistic 




















1.72 to 2.93, p=3.2410-9) and of mortality with test-confirmed COVID-19 (OR=4.29, 95% CI: 2.38 to 
7.72, p=1.2210-6), compared to e3e3s. For e3e4s versus e3e3s, these two associations were nominally 
statistically significant (at p<0.05), but with much smaller effect sizes. The e4e4 associations were similar 
after excluding 50,566 participants related to the 3rd-degree or closer for test positivity (e4e4 OR=2.30, 
95% CI: 1.73 to 3.07, p=1.3910-8) and for mortality with test-confirmed COVID-19 (e4e4 OR=4.53, 
95% CI: 2.39 to 8.61, p=3.8710-6). Additionally, the e4e4 association with either COVID-19 outcome 
was little changed after removing participants with diseases associated with ApoE e4 alleles [5] and 
COVID-19 severity [6], including dementia, hypertension, coronary artery disease (myocardial infarction 
or angina), or type 2 diabetes (Table 1), based on diagnoses recorded from baseline self-reports and 
hospital discharge records during follow-up to March 2017. ApoE e3e4s were modestly associated with 
test positivity overall, and the association tended to be less marked in disease-free samples (Table 1). In 
additional analyses, we tested associations with ApoE e2 alleles, which have been linked to beneficial 
health outcomes [5]. No associations were found between e2e3 and either of our COVID-19 outcomes 
(p>0.05, versus e3e3). Analyses for e2e2s associations were underpowered (n=2,427, 4 positives, and 1 
positive death).  
The results presented imply a recessive effect of the ApoE e4 allele. Only modest associations 
were present between the much more common e3e4 genotype and COVID-19 outcomes, similar to results 
for rs429358 (which separates 0, 1, and 2 copies of e4 alleles, OR=1.3, p=0.0026) reported for severe 
COVID-19 with respiratory failure in a recent additive effect genome-wide analysis [7]. ApoE e4e4 
associations with test positivity and mortality were little affected by excluding dementia and other ApoE 
e4 associated diagnoses reported before March 2017: future work should include recent pre-existing 
diagnoses. More data are needed on ApoE and COVID-19 associations in other ancestry groups, as 
numbers of UK Biobank participants of such groups are unfortunately too small for this analysis.  
In conclusion, ApoE e4e4 genotype is associated with COVID-19 test positivity at genome-wide 




















Similarly, the e4e4 genotype was associated with a four-fold increase in mortality after testing positive for 
COVID-19, in UK Biobank. Independent replications are needed to confirm our findings and mechanistic 
work is needed to understand how ApoE e4e4 results in the marked increase in vulnerability, especially 
for COVID-19 mortality. These findings also demonstrate that risks for COVID-19 mortality are not 





















Table 1 Risk of COVID-19 test positivity and mortality, comparing participants with ApoE e3e4 or e4e4 to e3e3 genotypes, in UK Biobank 
       COVID-19 positive  
vs. rest of study sample 
COVID-19 positive and died 
vs. rest** of study sample 







death rate per 105 
OR (95% CI)  P-value OR (95% CI)  P-value 
All           
e3e3 219,747 219,084 663 79 302 36 - - - - 
e3e4 88,882 88,561 321 42 361 47 1.20 (1.05, 1.37) 0.009 1.35 (0.92, 1.96) 0.121 
e4e4 8,767 8,708 59 13 673 148 2.24 (1.72, 2.93) 3.24E-9 4.29 (2.38, 7.72) 1.22E-6 
Excluding dementia    
e3e3 219,392 218,744 648 76 295 35 - - - - 
e3e4 88,558 88,263 295 34 333 39 1.13 (0.98, 1.29) 0.093 1.14 (0.76, 1.70) 0.536 
e4e4 8,676 8,618 58 13 669 151 2.27 (1.74, 2.98) 2.42E-9 4.53 (2.51, 8.16) 5.21E-7 
Excluding hypertension   
e3e3 147,332 146,958 374 31 254 21 - - - - 
e3e4 59,655 59,483 172 17 288 29 1.13 (0.94, 1.35) 0.186 1.39 (0.77, 2.51) 0.278 
e4e4 5,918 5,881 37 5 625 85 2.45 (1.75, 3.44) 2.10E-7 4.25 (1.65, 10.95) 0.003 
Excluding coronary artery disease   
e3e3 201,003 200,435 568 62 283 31 - - - - 
e3e4 80,850 80,590 260 33 322 41 1.14 (0.98, 1.32) 0.090 1.36 (0.89, 2.08) 0.153 
e4e4 7,973 7,923 50 10 627 126 2.23 (1.67, 2.98) 6.21E-8 4.23 (2.16, 8.26) 2.43E-5 
Excluding Type II diabetes   
e3e3 208,374 207,795 579 61 278 29 - -   
e3e4 84,620 84,342 278 30 329 36 1.18 (1.02, 1.36) 0.024 1.24 (0.80, 1.92) 0.338 
e4e4 8,391 8,336 55 12 655 144 2.36 (1.79, 3.12) 1.23E-9 5.05 (2.72, 9.39) 3.08E-7 
* adjusted for sex, age at death or age on 26th April, 2020 (the last date of death), assessment center in England, genotyping array type, and the top 
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